Jane Street’s TScan Therapeutics TCRX Stock Holding History

Jane Street’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$146K	Sell	144,421 -243,863	-63%	-$261K	﹤0.01%	10411
2025 Q4	$388K	Buy	388,284 +306,968	+378%	+$444K	﹤0.01%	8258
2025 Q3	$148K	Sell	81,316 -132,080	-62%	-$234K	﹤0.01%	9893
2025 Q2	$309K	Buy	+213,396	New	+$308K	﹤0.01%	7805
2024 Q4	–	Sell	-93,876	Closed	-$468K	–	10564
2024 Q3	$468K	Sell	93,876 -5,160	-5%	-$31.1K	﹤0.01%	7304
2024 Q2	$579K	Sell	99,036 -54,097	-35%	-$426K	﹤0.01%	6767
2024 Q1	$1.22M	Buy	153,133 +69,511	+83%	+$437K	﹤0.01%	5051
2023 Q4	$488K	Buy	+83,622	New	+$383K	﹤0.01%	6798
2022 Q3	–	Sell	-10,176	Closed	-$32K	–	10456
2022 Q2	$32K	Buy	+10,176	New	+$27.8K	﹤0.01%	9042
2022 Q1	–	Sell	-11,307	Closed	-$51K	–	11013
2021 Q4	$51K	Buy	+11,307	New	+$81.6K	﹤0.01%	9528

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Jane Street's TCRX Position: Q1 2026 in Review

Jane Street reduced its TScan Therapeutics (TCRX) stake by 63% in Q1 2026, selling an estimated $261K and leaving 144,421 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #10411.

Jane Street first reported a position in TCRX in Q4 2021 and has held it in 10 quarters since. The position peaked at $1.22M in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

Jane Street held 144,421 shares of TScan Therapeutics worth $146K as of Q1 2026.
Jane Street sold 243,863 TScan Therapeutics shares in Q1 2026, an estimated $261K.
TScan Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10411 holding.
Jane Street first reported a position in TScan Therapeutics in Q4 2021 and has held it in 10 quarters since.
Jane Street's TScan Therapeutics position peaked at $1.22M in Q1 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.